BUDGET IMPACT OF SELINEXOR COMBINATION REGIMENS IN PREVIOUSLY TREATED MULTIPLE MYELOMA

被引：0
|
作者：
Carter, J. A. [1 ]
Ijioma, S. [2 ]
Ray, D. [3 ]
机构：
[1] OPEN Hlth, Bethesda, MD USA
[2] Karyopharm Therapeut Inc, Marietta, GA USA
[3] Karyopharm Therapeut Inc, Newton, MA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE403
引用
收藏
页码：S131 / S131
页数：1
相关论文
共 50 条
  • [41] Racial differences in outcomes of patients with relapsed/refractory multiple myeloma treated with selinexor
    Cole, Craig
    Opalikhin, Anne Maria
    McCartney, Matthew
    Heideman, Caroline
    Pentapati, Swetha
    Wang, Ling
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] Selinexor in relapsed/refractory multiple myeloma
    Richter, Joshua
    Madduri, Deepu
    Richard, Shambavi
    Chari, Ajai
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2020, 11
  • [43] Efficacy of the Combination Therapy (ABCD) in Previously Treated Myeloma Patients
    Di Raimondo, F.
    Romano, A.
    Gorgone, A.
    Chiarenza, A.
    Cavalli, M.
    Berretta, S.
    Fiumara, P.
    Motta, G.
    Schinocca, L.
    Palumbo, G. A.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S143 - S143
  • [44] Treatment of multiple myeloma with selinexor: a review
    Huang, Qianlei
    Zhao, Ranran
    Xu, Lu
    Hao, Xinbao
    Tao, Shi
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [45] NETWORK META-ANALYSIS (NMA) OF ONCE WEEKLY SELINEXOR-BORTEZOMIB-DEXAMETHASONE (XVD) IN PREVIOUSLY TREATED MULTIPLE MYELOMA (MM)
    Dolph, M.
    Tremblay, G.
    Gilligan, A.
    Leong, H.
    VALUE IN HEALTH, 2021, 24 : S23 - S23
  • [46] Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma
    Tarek H. Mouhieddine
    Samir Parekh
    Hearn Jay Cho
    Joshua Richter
    Andrew DeCastro
    Jatin Shah
    Yosef Landesman
    Ajai Chari
    Sundar Jagannath
    Deepu Madduri
    Annals of Hematology, 2021, 100 : 3057 - 3060
  • [47] Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma
    Mouhieddine, Tarek H.
    Parekh, Samir
    Cho, Hearn Jay
    Richter, Joshua
    DeCastro, Andrew
    Shah, Jatin
    Landesman, Yosef
    Chari, Ajai
    Jagannath, Sundar
    Madduri, Deepu
    ANNALS OF HEMATOLOGY, 2021, 100 (12) : 3057 - 3060
  • [48] Selinexor for Refractory Multiple Myeloma Reply
    Chari, Ajai
    Vogl, Dan T.
    Jagannath, Sundar
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (20): : 1977 - 1978
  • [49] Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany
    Edin Basic
    Mathias Kappel
    Arpit Misra
    Leopold Sellner
    Boris A. Ratsch
    Dennis A. Ostwald
    The European Journal of Health Economics, 2020, 21 : 1351 - 1361
  • [50] Efficacy and safety of selinexor-based regimens for relapsed/refractory multiple myeloma: a systematic review of literature
    Masood, Adeel
    Iqbal, Qamar
    Ehsan, Hamid
    Davis, James A.
    Hansen, Doris K.
    Hashmi, Hamza
    ANNALS OF HEMATOLOGY, 2022, 101 (12) : 2601 - 2610
12345